Your browser doesn't support javascript.
loading
The effect of obesity pharmacotherapy on body composition, including muscle mass.
Argyrakopoulou, Georgia; Gitsi, Evdoxia; Konstantinidou, Sofia K; Kokkinos, Alexander.
Afiliación
  • Argyrakopoulou G; Diabetes and Obesity Unit, Athens Medical Center, 15125, Athens, Greece. gargyrakopoulou@gmail.com.
  • Gitsi E; Diabetes and Obesity Unit, Athens Medical Center, 15125, Athens, Greece.
  • Konstantinidou SK; Diabetes and Obesity Unit, Athens Medical Center, 15125, Athens, Greece.
  • Kokkinos A; First Department of Propaedeutic Internal Medicine, Medical School, National and Kapodistrian University of Athens, Laiko General Hospital, Athens, Greece.
Int J Obes (Lond) ; 2024 May 14.
Article en En | MEDLINE | ID: mdl-38745020
ABSTRACT
Obesity pharmacotherapy represents a promising approach to treating obesity and may provide benefits beyond weight loss alone. Maintaining or even increasing muscle mass during weight loss is important to overall health, metabolic function and weight loss maintenance. Drugs such as liraglutide, semaglutide, tirzepatide, and naltrexone/bupropion have shown significant weight loss effects, and emerging evidence suggests they may also have effects on body composition, particularly a positive influence on muscle mass. However, further research is needed to fully understand the mechanism of action of these drugs and their effects on muscle mass. Clinicians should consider these factors when developing an obesity treatment plan for an individual patient.

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Int J Obes (Lond) Asunto de la revista: METABOLISMO Año: 2024 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Int J Obes (Lond) Asunto de la revista: METABOLISMO Año: 2024 Tipo del documento: Article